

Optimizing Subphases for LCT-based Anti-Cancer drug response model

C&SBIO185 - Bplate

Tommy Thach, Dominic Pham, Breanna Remigio & Rachelle Le

Table of contents

01

Brief Background

02

Problem
Statement

03

Goal

04

Results

05

Limitations

06

Broader
Implications


The background is a light lavender color. It features several decorative elements: a large, thick, dark purple ribbon on the left side, looping and extending downwards; a smaller, similar ribbon at the bottom left; a fern frond in the top center; a leafy branch in the top right; and another leafy branch in the bottom right. There are also several small, solid purple dots scattered across the background.

01

Brief
Background


Introduction

- analyzes engineered breast cell cancer that express cell cycle reporter
- analyzes how different drugs impact cell cycle phases of cancer




Background Cont.

- Engineered breast cells treated with 5 drugs
 - Change in cells depend on quantity of dosage



Background Cont.

- Computational Method: Linear Chain Trick (LCT)
 - mean-field system of ordinary differential equations (ODEs)
 - capture oscillatory cell cycle behavior and drug effects on specific phases
 - parameter: number of cell cycle subphases





02

Problem Statement

Question

n

What are the optimal G1 and S/G2 sub-phases that should be used to lower the model's error rate?


The background is a light lavender color. It features several decorative elements: a large, thick, dark purple ribbon on the left side, looping and extending downwards; a smaller, similar ribbon at the bottom left; a fern frond in the top center; and a leafy branch in the top right. There are also several small, solid purple dots scattered across the background.

03

Goals & Methods




Goals

- Recreate the LCT model
 - Find optimal number of G1 and S/G2 sub-phases that should be used to lower the model's error rate
 - Change small parts of code and combine them to make sure they still work
 - Could we find a more optimal number?
- 



Methods


- An ODE model was used to predict the number of cells in the G1 and G2 phases of the cell cycle
 - Tested five different combinations of subphases: (12, 20), (12, 32), (8, 16), (8,24), and (8, 32)
 - Also tested across three different conditions of drugs: doxorubicin, gemcitabine, and lapatinib
 - To compare findings, we plotted the number of G1 cells and S/G2 cells over times and also compared the sum of squared errors of the model to original data
- 

The background is a light lavender color. It features several decorative elements: a large, thick, dark purple ribbon forming a loop on the left side; a smaller, similar ribbon loop at the bottom left; a fern frond in the top center; a leafy branch in the top right; and another leafy branch in the bottom right. There are also several small, solid dark purple dots scattered across the page.

04

Results

Results




- Highest errors for $G1 = 12$
- Lowest errors for $G1 = 8$


Results

Highest Error for Gemcitabine: (G1, G2) = (12, 32)

Gemcitabine - G1 Phase
G1 = 12, G2 = 32




Gemcitabine - G2 Phase
G1 = 12, G2 = 32




Results

Lowest Error for Gemcitabine: $(G1, G2) = (8, 32)$


Gemcitabine - G1 Phase
 $G1 = 8, G2 = 32$




Gemcitabine - G2 Phase
 $G1 = 8, G2 = 32$




- Combination with lowest error varies across the different drugs



Gemcitabine - G1 Phase
G1 = 8, G2 = 20



Gemcitabine - G1 Phase
G1 = 8, G2 = 32



- Minor differences between the two as they keep relatively the same shape
- Final numbers for G2 = 32 are more accurate

The background is a light lavender color. It features several decorative elements: a large purple ribbon on the left side, a smaller purple ribbon at the bottom left, and stylized purple foliage (leaves and ferns) in the top right and bottom right corners. There are also several small purple dots scattered across the background.

05

Limitations

Limitations



Base Design

Errors from fundamental design will carry over




Clinically Unproven

Drug combinations and/or sequences outputted by model are still yet to be tested on real patients



Time Constraints

Unable to implement all possible methods to find optimal subphases



Q6 Broader Implications

Optimized Drug Combinations & Sequencing



Drug Combinations

The LCT model can be used to predict the impact of different drug combinations of cell cycle behavior and find cell numbers associated. Analyzing how drug combinations target cell cycle phases, can gain insight on whether combining specific drugs have synergistic or antagonistic effects.



Drug Sequencing

The findings from this research can inform the development of rational and effective drug sequencing strategies for cancer treatment by considering the cell cycle effects of individual drugs, predicting drug responses to sequential treatments, and validating the efficacy of personal treatment plans for patients through experimental studies.



Thanks

CREDITS: This presentation template was created by **Slidesgo**, including icons by **Flaticon**, and infographics & images by **Freepik**